This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.
Companies in this article
FDA notified healthcare professionals of new risk information added to the Warnings and Precautions, Contraindications, and Clinical Pharmacology sections of the antiviral drug Invirase (saquinavir), describing a potential change in the electrical activity of the heart when Invirase is used with another antiviral medication, Norvir (ritonavir).
This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.